Flagyl

Selected form

Method of action: Antialcoholic, Antibiotics And Chemotherapeutics For Dermatological Use, Antiprotozoal, Antiulcer, Bactericidal

Treatment option: Abscess, Brain Abscess, Infection, Bone Infection, Peritonitis, Pneumonia, Wound Infection, Sepsis, Cellulite

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flagyl

Property	Description
Active ingredient	Metronidazole (INN)
Form	Oral Tablets, Intravenous Solution, Topical Preparations
Pharmacological class	Nitroimidazole Antimicrobial Agent
Common purpose	To treat infections caused by specific bacteria and parasites
Origin	Synthetic Derivative (Prescription-only)

Flagyl is a globally recognized brand name for the anti-infective medication containing the active ingredient metronidazole (INN). This drug is classified as a synthetic nitroimidazole compound, a class clinically recognized for its potent activity against microorganisms that thrive in oxygen-depleted environments. Flagyl is a prescription-only (Rx) product in the United States and many other countries.

Metronidazole is formally categorized as an Anti-Bacterial Agent and an Antiprotozoal Agent, reflecting its ability to combat both anaerobic bacteria and specific protozoal parasites. Pharmacological studies have widely confirmed its rapid onset of bactericidal activity under appropriate reducing conditions. The general purpose of this medication is the targeted clearance and control of infections caused by these specific categories of harmful microorganisms.

Composition, Forms, and General Therapeutic Purpose

The medicine contains metronidazole as its single active ingredient. It is available in multiple pharmaceutical preparations to facilitate administration across several routes, including oral tablets and capsules, a sterile intravenous solution for parenteral delivery in acute cases, and various topical or vaginal preparations. This comprehensive availability across oral, intravenous, and topical routes ensures that the drug can be used against both systemic internal infections and infections confined to localized areas.

Regulatory References

Metronidazole: MedlinePlus Drug Information

What side effects are possible with Flagyl?

Flagyl (metronidazole) is an antibiotic that can cause side effects ranging from common gastrointestinal upset to rare, serious neurological events. It is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. It is also contraindicated in patients who have taken disulfiram within the last two weeks, due to the risk of psychotic reactions.

Common Side Effects

Commonly reported side effects often involve the digestive system and may include:

Nausea, vomiting, or abdominal cramping
Diarrhea
An unpleasant, sharp metallic taste in the mouth
Headache
Loss of appetite

These common side effects may sometimes be managed by taking the medication with food, but it is important to consult a healthcare provider if they are persistent or severe.

Serious Side Effects and Warnings

Flagyl carries a warning regarding the potential for carcinogenicity, based on studies in mice and rats; therefore, its use is reserved for approved indications only. Rare but serious side effects require immediate medical attention and include:

Central and Peripheral Nervous System Effects: Seizures, encephalopathy (abnormal brain function), and peripheral neuropathy (tingling, numbness, or pain in the hands or feet). These symptoms generally resolve upon discontinuation of the drug.
Severe Allergic/Skin Reactions: Including hives, blistering, or widespread rash.
Hepatotoxicity: Severe liver injury, particularly in patients with Cockayne syndrome, is a contraindication.

Drug-Alcohol Interaction

Consumption of alcohol, or products containing propylene glycol, during and for at least three days after metronidazole therapy is strictly prohibited. This combination can cause a severe disulfiram-like reaction, characterized by flushing, headaches, nausea, vomiting, and abdominal cramps.

Overdose and Emergency Response

Overdose and When to Seek Help

Metronidazole (Flagyl) overdose information is based on reports of both accidental and attempted high-dose exposures, including single oral doses reported up to 15 grams. Exposures in this range have been associated with a specific cluster of symptoms, primarily affecting the gastrointestinal and nervous systems.

Overdose Presentations

Documented signs of overdose have included nausea, vomiting, and loss of muscle coordination (ataxia). More serious neurological effects, such as convulsive seizures and damage to the peripheral nerves (peripheral neuropathy), have been reported in cases involving very high cumulative doses over several days of treatment.

Required Emergency Actions

There is no specific antidote available to reverse the effects of a metronidazole overdose. Management consists solely of providing symptomatic and supportive therapy to address the manifested symptoms and maintain essential bodily functions.

If an overdose is suspected or a large amount has been consumed, immediate medical attention is required. Contacting emergency services or a poison control center for guidance on supportive management and monitoring is a necessary step.

Therapeutic Uses of Flagyl

What Flagyl Treats: Main Uses and Benefits

Metronidazole (Flagyl) is commonly used for managing conditions characterized by specific anaerobic bacteria and protozoal parasites, contributing to improved comfort and easing systemic and localized distress. The medication is used to address infections across domains including the reproductive system, gastrointestinal (GI) tract, skin, blood, and central nervous system.

Its primary use involves addressing the causative organisms, which is relevant in clinical settings that involve acute or unstable symptom patterns. Common scenarios range from treating serious systemic disease and deep-seated abscesses, where it may assist with managing pronounced symptoms like high fever and malaise, to managing localized conditions such as bacterial vaginosis (BV) and dental infections, where it helps address symptoms like pain, odor, and discharge. It is also commonly applied in conditions marked by parasitic infestation, including trichomoniasis, amebiasis, and giardiasis.

Quick Fact: Relief for Symptomatic Distress
Metronidazole is commonly used to help with symptomatic relief in acute episodes of infectious diarrhea and pelvic pain caused by susceptible anaerobic and protozoal organisms.

Eligibility and Restrictions for Use

Flagyl (metronidazole) is an antibiotic and antiprotozoal medicine whose use is strictly defined by regulatory documents based on patient status and concurrent conditions.

The drug is contraindicated (must not be used) for:

Patients with a history of hypersensitivity or allergy to metronidazole or other nitroimidazole medicines.
Patients with Cockayne syndrome, due to the high risk of severe, irreversible hepatotoxicity and acute liver failure.
Patients who have taken disulfiram (Antabuse) within the preceding two weeks, due to the risk of psychotic reactions.
Patients with trichomoniasis during the first trimester of pregnancy (for some formulations).

Use requires special consideration or caution for individuals with:

Severe hepatic (liver) impairment (Child-Pugh C), where a reduced dose is recommended, and use of extended-release tablets is generally not recommended unless benefits outweigh risks.
Central Nervous System (CNS) diseases, such as a history of seizures or peripheral neuropathy.
Severe or end-stage renal disease, where monitoring is necessary due to the potential for accumulation of metabolites.

Age-related rules indicate that the safety and efficacy of capsules, liquid, and standard tablets for non-amebiasis indications have not been established for the pediatric population. The extended-release tablets should only be used in adolescent females after the start of menstruation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metronidazole (Flagyl) has formally documented interactions that impose specific regulatory constraints on co-administration. Certain combinations are strictly prohibited. The use of Disulfiram within the last two weeks before metronidazole therapy is contraindicated due to the documented risk of psychotic reactions. Furthermore, the consumption of alcoholic beverages or products containing propylene glycol is prohibited during treatment and for a mandatory period of at least three days (72 hours) following the final dose, based on the risk of a disulfiram-like adverse reaction.

Interactions involving metabolic enzymes are officially documented. Co-administration with agents that inhibit CYP450 enzymes (like Cimetidine) may decrease the clearance and prolong the half-life of metronidazole. Conversely, co-administration with enzyme inducers (like Phenytoin or Phenobarbital) may accelerate metronidazole elimination, potentially reducing its plasma levels.

Other clinically significant interactions involve exposure modification and pharmacodynamic potentiation. Metronidazole is documented to increase the plasma concentration and toxicity risk of Busulfan and may also elevate serum levels of Lithium. Additionally, the drug potentiates the effect of oral anticoagulants (e.g., Warfarin), which may lead to a prolongation of prothrombin time. In patients with severe hepatic impairment, the drug's clearance is substantially reduced, leading to potential plasma accumulation.

Mechanism of Action

The drug functions as an inactive prodrug that must undergo reductive bioactivation to yield the active cytotoxic intermediate. This process is strictly limited to environments lacking oxygen, where specific microbial electron-transport proteins, such as Ferredoxin, are present. This enzyme system donates electrons to the drug molecule, resulting in selective targeting of susceptible microorganisms and confining the cytotoxic action to the microbe.

The reductive activation yields a highly unstable nitro radical anion intermediate. This molecule is highly reactive and cytotoxic and immediately initiates a cascade of irreversible DNA damage by causing strand breakage and inhibiting nucleic acid synthesis within the target cell. This primary mechanistic domain results in the death of the pathogenic cell, a key physiological consequence that results in the degradation of the microbial cell population.

The entire mechanism is fundamentally constrained by the surrounding environment. The presence of oxygen rapidly neutralizes the cytotoxic radical intermediates, thereby preventing them from interacting with the microbial DNA. This mechanistic limitation ensures the drug is primarily relevant in systems where targeted pathway adjustment for anaerobic processes is required, and it explains why the mechanism does not proceed in aerobic microorganisms.

Dosage and Administration Information

Metronidazole (Flagyl) is administered via the oral or intravenous (IV) infusion route, a procedural distinction often dependent on the severity and site of the infection. The IV route is typically utilized for the initial management of serious systemic infections, followed by a transition to oral administration for the completion of the regimen. Dosage is specific to the indication and patient, but common adult regimens include a maintenance dose of 7.5 mg/kg every six hours for anaerobic infections or a 2 g single dose for trichomoniasis. Treatment courses are standardized and short-term, typically ranging from a single day up to 5 to 10 days for amebiasis.

Specific administration conditions govern proper intake based on the formulation. Immediate-release oral tablets may be taken with or without food. In contrast, the extended-release tablets must be swallowed whole and taken without food to preserve their release mechanism. For IV use, each dose must be infused over a period of one hour. Adjustments are made for specific populations: a 50% dose reduction is recommended for individuals with severe hepatic impairment. If a dose is missed, the recommendation is to take it as soon as remembered, unless it is near the time of the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metronidazole (Flagyl)

This section summarizes the official research evidence and study landscape for metronidazole, describing what clinical trials and reviews have explored and what remains uncertain, without providing any clinical advice or recommendations.

Evidence for Systemic Anaerobic Bacterial Infections

Research concerning severe, systemic anaerobic bacterial infections, such as those in the bloodstream or deep tissues, is built upon a broad body of evidence, including comparative studies. Randomized controlled trials (RCTs) and systematic reviews was evaluated in research that explores standard treatment approaches for these infections. Studies monitored mortality/survival rates and the need for escalation of antibiotic therapy. For instance, some studies explored whether administration intervals of every 12 hours achieved similar measurements of short-term outcomes to an every-8-hour interval. Results apply only to the populations studied, and certain complex infections may have been excluded from the analysis.

A key research limitation is that trials rarely involve comparing metronidazole alone against a placebo. Data for certain groups, such as those with central nervous system infections, remain insufficient across some trials. The evidence quality varies across studies, and for some outcomes related to the empirical use of metronidazole, certainty remains low due to a lack of large, definitive RCTs.

Evidence for Trichomoniasis (T. vaginalis)

Research exploring this protozoal infection primarily involves RCTs that compared different ways of administering metronidazole, such as a single high-dose regimen versus a multi-dose regimen. The main outcomes studied were microbiological cure and clinical cure (resolution of symptoms like vaginal discharge). Comparative studies reported that multi-dose regimens may be associated with a lower rate of the parasite reappearing at the follow-up test. The tendency for retesting positive for the parasite is a notable pattern, and limited information is available from studies comparing these regimens among men.

Key Research Gaps and Uncertainties

Research provides context but not individual predictions. For common vaginal infections like BV, the most significant gap is the lack of robust evidence on long-term management strategies to prevent the high rate of recurrence documented across studies. For systemic anaerobic infections, comparative evidence is often lacking, as trials typically evaluate metronidazole in combination with another drug rather than comparing metronidazole alone to an alternative agent.

Frequently Asked Questions (FAQ)

Common questions about Flagyl (FAQ)

Q: How quickly does Flagyl typically start working for an infection?

A: Official information indicates that metronidazole, the active ingredient in Flagyl, has rapid bactericidal activity. This means the drug begins its action of killing susceptible bacteria and parasites shortly after it is activated inside the microbe. The timeline for symptom improvement may vary based on the specific infection being treated.

Q: Can Flagyl interact with common blood pressure medications?

A: Regulatory information notes that Flagyl can interact with medicines that affect certain liver enzymes (CYP450). This means that some blood pressure medications may have their concentration in the body altered when taken alongside Flagyl. Patients are advised to ensure their healthcare provider is aware of all current medications before starting treatment.

Q: Is Flagyl generally considered safe during pregnancy?

A: The use of Flagyl during pregnancy requires careful professional assessment. Official prescribing information states that its use for trichomoniasis is contraindicated (not allowed) during the first trimester. For other conditions or later trimesters, the provider weighs the potential benefits against any possible risks.

Q: Can Flagyl cause a temporary change in appetite?

A: Yes, loss of appetite, also known as anorexia, is listed in the official adverse reactions section as a commonly reported side effect of Flagyl. If persistent loss of appetite is experienced, consultation with a healthcare provider is recommended.

Q: What is the typical duration of treatment with Flagyl for different infections?

A: The duration of Flagyl treatment is short-term and highly dependent on the type of infection being treated. For some conditions, a single dose may be prescribed, while for others, such as amebiasis, the course may be 5 to 10 days. The specific length of treatment is determined by the healthcare provider.

Q: How long does Flagyl stay in your system after the last dose?

A: According to the official pharmacokinetic data, the average elimination half-life of metronidazole in healthy adults is around eight hours. It takes several half-lives for a medication to be completely eliminated from the body. This information informs the required period of avoiding alcohol after treatment.

Q: Does Flagyl interact with antidepressants or anxiety medications?

A: Some official drug interaction databases indicate metronidazole may interact with certain antidepressants, potentially increasing the risk of adverse cardiac events. It is essential that all current medications, including those for mental health, are disclosed to the healthcare provider to assess potential interaction risks.

Q: Is it common for Flagyl to cause a rash?

A: A rash or hives can be a reported adverse effect. While severe allergic reactions, including a widespread rash, are listed as rare and serious side effects, less severe rashes have been reported. Any new or worsening rash is typically considered important to report to a healthcare provider.

Q: Are there any known drug interactions between Flagyl and common acid reducers?

A: Official documents list a known interaction with Cimetidine, a specific type of acid reducer, which can potentially increase the levels of Flagyl in the body. It is important for patients to inform their prescriber about all medications, including prescription or over-the-counter acid reducers.

Q: Is Flagyl the same kind of antibiotic as penicillin?

A: No, Flagyl and penicillin are different types of anti-infective medications. Flagyl belongs to the nitroimidazole class and is specifically active against anaerobic bacteria and certain parasites. Penicillin belongs to the beta-lactam class and targets a different range of microorganisms.

Q: What should I do if I miss a dose of Flagyl?

A: Regulatory instructions advise that if a dose is missed, it should be taken as soon as remembered. However, if it is very close to the time for the next scheduled dose, the missed dose should be skipped to resume the regular schedule. Official instructions advise against taking two doses simultaneously.

Q: Are there any specific vitamins or supplements that interact with Flagyl?

A: Regulatory warnings primarily focus on prescription medications. However, patients are generally advised to disclose all products, including vitamins, herbal products, or dietary supplements, to their prescribing doctor or pharmacist.

Q: Is Flagyl safe to take for children?

A: For many uses and formulations of Flagyl, official safety and effectiveness in the pediatric population have not been established. The decision to use Flagyl in children and the appropriate dosage is highly specific and is determined by a healthcare professional.

Q: Can older adults or seniors take Flagyl safely?

A: Official prescribing information advises caution when selecting a dose for senior patients, often recommending a starting dose on the lower end of the range. This is primarily due to the higher likelihood of reduced liver or kidney function in older adults.

Q: Does Flagyl treat both bacterial and parasitic infections?

A: Yes, metronidazole is categorized by regulatory bodies as both an anti-bacterial agent and an antiprotozoal agent. This dual classification reflects its activity against susceptible anaerobic bacteria and specific protozoal parasites.

Q: Why is Flagyl often used for dental infections?

A: The drug is indicated for serious infections caused by susceptible anaerobic bacteria. Since many severe infections involving the gums, teeth, or deep oral tissues are caused by these types of bacteria, Flagyl is frequently considered for treatment.

Q: What research supports the use of Flagyl for C. difficile infection?

A: Metronidazole is widely recognized and recommended in clinical practice guidelines published by public health authorities for the treatment of C. difficile infection. This approach is informed by clinical data on its activity against the specific anaerobic bacteria causing the infection.

Q: Is it true that Flagyl can cause dark urine?

A: Yes, official regulatory documents state that a darkening of the urine has been observed in some patients. This change in color is attributed to a metronidazole metabolite.

Q: Why do some people feel dizzy or lightheaded while on Flagyl?

A: Dizziness and vertigo (a sense of spinning) are listed as potential adverse reactions in the official prescribing information. The drug also carries warnings about Central Nervous System effects, which may contribute to these feelings.

Q: Is it normal to feel tired or fatigued when taking Flagyl?

A: While tiredness or fatigue is not consistently listed as a common side effect, official documents do note general neurological symptoms like malaise (a general feeling of being unwell) and weakness. Any persistent fatigue is advised to be discussed with a healthcare professional.

Q: Does Flagyl need to be stored in the refrigerator?

A: No. Official storage instructions state that oral tablets should be kept at a controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication should not be frozen or stored in areas that may expose it to excess heat or moisture.

Q: Is Flagyl effective for yeast infections?

A: No, Flagyl is not indicated for the treatment of yeast infections, which are caused by fungi. Official warnings state that a yeast infection (moniliasis) that was previously unrecognized may become more noticeable after treatment with Flagyl.

Q: Can Flagyl be used to treat bacterial vaginosis (BV)?

A: Yes, metronidazole is officially indicated for the treatment of Bacterial Vaginosis. It is an established treatment option for this specific condition.

Q: Are there different forms of Flagyl, like a cream or a gel?

A: The active ingredient, metronidazole, is available in various forms, including oral tablets, intravenous solutions, and topical or vaginal preparations. These preparations, which can include gels or creams, allow the drug to be used for both systemic and localized infections.

Q: Why is Flagyl not effective against viral infections?

A: The way Flagyl works is highly specific: it targets the DNA of anaerobic bacteria and protozoa through a unique activation process. Viruses lack this internal machinery, which is why Flagyl and other antibiotics are ineffective against viral illnesses like the common cold or flu.

Q: Is it normal to have a slight headache while taking Flagyl?

A: Yes, headache is listed in the official prescribing information as a commonly reported side effect when taking metronidazole. If a headache is severe or persistent, consultation with a healthcare provider is appropriate.

Q: What kind of infections does the IV form of Flagyl treat?

A: The intravenous (IV) form of Flagyl is reserved for serious, systemic infections caused by susceptible anaerobic bacteria. This includes severe conditions such as infections inside the abdomen (intra-abdominal infections) or bacterial infections of the bloodstream (septicemia).

Q: Can men also use Flagyl for certain infections?

A: Yes. Flagyl is indicated for use in both men and women for infections such as amebiasis. It is also used to treat male partners of women diagnosed with trichomoniasis to prevent reinfection.

Q: Is there any research on long-term effects of using Flagyl?

A: The drug label carries a boxed warning based on animal studies showing a potential for carcinogenicity. Due to this, the drug’s use is reserved for approved indications only, and the label warns against prolonged or unnecessary use due to the potential for peripheral neuropathy (nerve damage).

Q: Why is Flagyl often prescribed with a meal?

A: While immediate-release Flagyl can be taken with or without food, taking it with a meal or snack is often recommended. This is a common strategy employed by prescribers to help reduce the occurrence or severity of common gastrointestinal side effects like nausea or stomach upset.

Q: How long should I wait after a dose to drive or operate machinery?

A: Official safety information advises patients to avoid driving or operating machinery if they experience certain side effects. These can include dizziness, confusion, or visual disturbances, which are listed as potential adverse reactions to the medication.

Q: Why is Flagyl sometimes used before surgery?

A: Metronidazole injection is used in a preventative capacity before certain surgical procedures, particularly those involving the gastrointestinal tract. This prophylactic use is intended to reduce the risk of post-operative infections from anaerobic bacteria.

Q: Are there alternative names or brand names for the drug metronidazole?

A: Yes, Flagyl is a globally recognized brand name. The active ingredient is metronidazole, which is also widely available as a generic drug under that name, as well as other brand names.

Q: Does taking Flagyl require any special diet restrictions (besides alcohol)?

A: Yes, in addition to strictly avoiding alcohol, official warnings also prohibit the consumption of products containing propylene glycol during treatment and for at least three days afterward. This combination can also cause the unpleasant disulfiram-like reaction.

Q: How effective is Flagyl against H. pylori?

A: Metronidazole is officially indicated as part of a multi-drug regimen for treating H. pylori infection. It is typically combined with other medications, such as a proton pump inhibitor, to target the bacteria and assist in the management of associated ulcers.

How should Flagyl be stored and disposed of?

How to Store and Dispose of Flagyl (Metronidazole)

The official storage and disposal requirements for metronidazole are established by regulatory agencies to maintain product quality and safety.

Requirement	Official Statement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze or expose to excess heat.
Protection	Keep the medication in a tightly closed, light-resistant container. Protect from light and excess moisture, avoiding storage in areas like the bathroom.
Child Safety	Keep all medication strictly out of the reach and sight of children, utilizing child-resistant closures where provided.
Disposal	Dispose of unused or expired medicine through official drug take-back programs. If no program is available, mix with an unappealing substance (like dirt or used coffee grounds) and place in a sealed bag in the household trash. Do not flush the medication down a toilet or pour it down a drain.